CervoMed Inc
cervomed.comCervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, with a primary focus on dementia with Lewy bodies (DLB). The company generates no product revenue, operating entirely on capital raised through equity financing, including a 2024 private placement of 2,532,285 units that raised aggregate gross proceeds of up to approximately $149.4 million, completed April 1, 2024. CervoMed is incorporated in Delaware and operates as a pre-commercial drug development company, with its wholly-owned subsidiary EIP Pharma, Inc. as the primary operating entity following a merger effective August 16, 2023. The company has no disclosed commercial competitors in the filing excerpts provided.
Products & Services
CervoMed's pipeline targets neurodegenerative diseases including dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and related central nervous system conditions. Specific drug candidates and their clinical stages are not detailed in the available filing excerpts.
Revenue Model
CervoMed has no product revenue as of its 10-K filed March 13, 2026. Operations are funded through equity capital markets, including private placements. The 2024 Private Placement raised up to approximately $149.4 million in gross proceeds.
Customers & Markets
End market is patients with neurodegenerative diseases, primarily dementia with Lewy bodies and Alzheimer's disease. No commercial customers exist as of the filing date. Regulatory pathways include FDA review and EMA Centralized Procedure for neurodegenerative disease treatments in the EEA.
Geographic Exposure
CervoMed is a U.S.-incorporated (Delaware) company subject to FDA oversight domestically and pursuing EMA regulatory pathways for the European Economic Area. Specific headquarter address is not disclosed in the available filing excerpts.
Financial Snapshot
Loading...
